Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paclitaxel nanosomal - Intas Pharmaceuticals

Next Previous
Drug Profile

Paclitaxel nanosomal - Intas Pharmaceuticals

Latest Information Update: 26 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intas Pharmaceuticals; Jina Pharmaceuticals
  • Developer Intas Pharmaceuticals
  • Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inhibitors; Immunosuppressants; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 10 Mar 2025 Jina Pharmaceuticals plans a phase III trial for Ovarian cancer including ovarian cancer including Fallopian tube and/or primary Peritoneal cancer (Second-line therapy or greater, Recurrent) (IV) in April 2025 (NCT06867562)
  • 09 Sep 2022 Efficacy and adverse events data from a phase II trial in Breast cancer presented at the 47th European Society for Medical Oncology Congress (ESMO-2022)
  • 24 Sep 2021 Discontinued - Phase-II/III for Breast cancer (Metastatic disease, Second-line therapy or greater) in India (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top